Literature DB >> 2225298

The prophylactic use of octreotide in a patient with ovarian carcinoid and valvular heart disease.

J T Watson1, N H Badner, M J Ali.   

Abstract

This case report describes the use of octreotide, a long-acting somatostatin analogue, in the management of a patient with an ovarian carcinoid tumour and severe cardiac valvular disease. This patient underwent laparotomy and tumour resection without complication. Anaesthesia was induced with midazolam, fentanyl, and vecuronium, and maintained with isoflurane as well as additional fentanyl and vecuronium. However, we feel that it was the use of octreotide that prevented a life-threatening crisis intraoperatively, and recommend its use in patients with carcinoid syndrome undergoing anaesthesia and surgery.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2225298     DOI: 10.1007/BF03006540

Source DB:  PubMed          Journal:  Can J Anaesth        ISSN: 0832-610X            Impact factor:   5.063


  19 in total

1.  Ketanserin in the preoperative and intraoperative management of a patient with carcinoid tumor undergoing tricuspid valve replacement.

Authors:  P A Casthely; M Jablons; R B Griepp; M A Ergin; K Goodman
Journal:  Anesth Analg       Date:  1986-07       Impact factor: 5.108

2.  Anesthesia for ligation of the hepatic artery in a patient with carcinoid syndrome.

Authors:  A U Patel; R Miller; R R Warner
Journal:  Anesthesiology       Date:  1977-09       Impact factor: 7.892

3.  Octreotide--a synthetic somatostatin.

Authors: 
Journal:  Med Lett Drugs Ther       Date:  1989-07-14       Impact factor: 1.909

4.  Anaesthesia for the carcinoid syndrome: a report of nine cases.

Authors:  R Miller; A U Patel; R R Warner; I H Parnes
Journal:  Can Anaesth Soc J       Date:  1978-05

5.  Carcinoid syndrome: its relevance to the anaesthetist.

Authors:  R A Mason; P A Steane
Journal:  Anaesthesia       Date:  1976-03       Impact factor: 6.955

6.  SMS 201-995 and provocation tests in preparation of patients with carcinoids for surgery or hepatic arterial embolization.

Authors:  H Ahlman; L Ahlund; A Dahlström; J Martner; O Stenqvist; U Tylén
Journal:  Anesth Analg       Date:  1988-12       Impact factor: 5.108

7.  Carcinoid syndrome: the combined use of ketanserin and octreotide in the management of an acute crisis during anaesthesia.

Authors:  E W Hughes; B P Hodkinson
Journal:  Anaesth Intensive Care       Date:  1989-08       Impact factor: 1.669

8.  Valve replacement in carcinoid syndrome. Anaesthetic management for tricuspid and pulmonary valve surgery.

Authors:  M S Nielsen; J M Manners
Journal:  Anaesthesia       Date:  1979-05       Impact factor: 6.955

9.  Somatostatin, anaesthesia, and the carcinoid syndrome. Peri-operative administration of a somatostatin analogue to suppress carcinoid tumour activity.

Authors:  R C Roy; R F Carter; P D Wright
Journal:  Anaesthesia       Date:  1987-06       Impact factor: 6.955

10.  The cardiovascular effects of vecuronium (ORG NC45) and pancuronium in patients undergoing coronary artery bypass grafting.

Authors:  R B Morris; M K Cahalan; R D Miller; P L Wilkinson; A L Quasha; S L Robinson
Journal:  Anesthesiology       Date:  1983-05       Impact factor: 7.892

View more
  2 in total

1.  Octreotide for carcinoid syndrome.

Authors:  A McCrirrick; J Hickman
Journal:  Can J Anaesth       Date:  1991-05       Impact factor: 5.063

Review 2.  Shifting Paradigms in the Pathophysiology and Treatment of Carcinoid Crisis.

Authors:  Jessica E Maxwell; Boris Naraev; Daniel M Halperin; Michael A Choti; Thorvardur R Halfdanarson
Journal:  Ann Surg Oncol       Date:  2022-02-14       Impact factor: 5.344

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.